Education
About Us
Working with TipRanks
Follow Us
Cannara Biotech (LOVFF)
OTHER OTC:LOVFF
Total Valuation
Cannara Biotech has a market cap or net worth of $121.05M. The enterprise value is $149.75M.
Market Cap$121.05M
Enterprise Value$149.75M
Share Statistics
Cannara Biotech has 94,895,900 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding94,895,900
Owned by Insiders26.89%
Owned by Institutions―
Financial Efficiency
Cannara Biotech’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.
Return on Equity (ROE)―
Return on Assets (ROA)―
Return on Invested Capital (ROIC)―
Return on Capital Employed (ROCE)―
Revenue Per Employee232.79K
Profits Per Employee28.36K
Employee Count461
Asset Turnover―
Inventory Turnover―
Valuation Ratios
The current PE Ratio of Cannara Biotech is 12.4. Cannara Biotech’s PEG ratio is 0.00.
PE Ratio12.4
PS Ratio0.00
PB Ratio0.00
Price to Fair Value―
Price to FCF0.00
Price to Operating Cash Flow7.86
PEG Ratio0.00
Income Statement
In the last 12 months, Cannara Biotech had revenue of 107.32M and earned 13.08M in profits. Earnings per share was 0.14.
Revenue107.32M
Gross Profit47.22M
Operating Income22.20M
Pretax Income18.10M
Net Income13.08M
EBITDA28.18M
Earnings Per Share (EPS)0.14
Cash Flow
In the last 12 months, operating cash flow was 19.18M and capital expenditures -6.36M, giving a free cash flow of 12.82M billion.
Operating Cash Flow19.18M
Free Cash Flow12.82M
Free Cash Flow per Share0.14
Dividends & Yields
Cannara Biotech pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.39
52-Week Price Change144.23%
50-Day Moving Average1.22
200-Day Moving Average1.13
Relative Strength Index (RSI)55.40
Average Volume (3m)2.46K
Important Dates
Cannara Biotech upcoming earnings date is Jan 26, 2026, Before Open (Confirmed).
Last Earnings DateNov 24, 2025
Next Earnings DateJan 26, 2026
Ex-Dividend Date―
Financial Position
Cannara Biotech as a current ratio of ―, with Debt / Equity ratio of 48.15%
Current Ratio―
Quick Ratio―
Debt to Market Cap―
Net Debt to EBITDA―
Interest Coverage Ratio―
Taxes
In the past 12 months, Cannara Biotech has paid 5.02M in taxes.
Income Tax5.02M
Effective Tax Rate―
Enterprise Valuation
Cannara Biotech EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.
EV to Sales―
EV to EBITDA―
EV to Free Cash Flow―
EV to Operating Cash Flow―
Balance Sheet
Cannara Biotech has $14.36M in cash and marketable securities with $41.58M in debt, giving a net cash position of -$27.22M billion.
Cash & Marketable Securities$14.36M
Total Debt$41.58M
Net Cash-$27.22M
Net Cash Per Share-$0.29
Tangible Book Value Per Share―
Margins
Gross margin is 44.57%, with operating margin of ―, and net profit margin of ―.
Gross Margin44.57%
Operating Margin―
Pretax Margin―
Net Profit Margin―
EBITDA Margin―
EBIT Margin―
Analyst Forecast
The average price target for Cannara Biotech is ―, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target―
Price Target Upside―
Analyst ConsensusModerate Buy
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―